Lazard Asset Management
GCVRZ

Lazard Asset Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Lazard Asset Management’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-28
Closed – – 1093
2017
Q2 		$0 Buy
+28
New +$11 ﹤0.01% 1083

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Lazard Asset Management's GCVRZ Position: Q3 2017 in Review

Lazard Asset Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q3 2017, closing a stake of 28 shares.

Lazard Asset Management first reported a position in GCVRZ in Q2 2017 and held it in 1 quarter. The position peaked at $0 in Q2 2017. 111 funds tracked by Wall St. Rank hold GCVRZ as of Q3 2017.

  • Lazard Asset Management reported no remaining Sanofi Contingent Value Rights position as of Q3 2017 after selling out during the quarter.
  • Lazard Asset Management sold 28 Sanofi Contingent Value Rights shares in Q3 2017.
  • Lazard Asset Management first reported a position in Sanofi Contingent Value Rights in Q2 2017 and held it in 1 quarter.
  • Lazard Asset Management's Sanofi Contingent Value Rights position peaked at $0 in Q2 2017.
  • 111 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q3 2017.

Based on Lazard Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.